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ABSTRACT

Background
Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic stroke, prior studies have found low rates of administration. Recent guidelines and regulatory agencies have advocated for increased tPA administration in appropriate patients, but it is unclear how many patients actually receive tPA.
Objective
To determine whether national rates of tPA use for ischemic stroke have increased over time.
Methods
We identified all patients with a primary diagnosis of ischemic stroke from years 2001-2006 in the National Hospital Discharge Survey, a nationally representative sample of inpatient hospitalizations, and searched for procedure codes for intravenous thrombolytic administration.
Clinical and demographic factors were obtained from the survey and multivariable logistic regression used to identify independent predictors associated with thrombolytic use. Although tPA administration for ischemic stroke has increased nationally in recent years, the overall rate of use remains very low. Larger hospitals were more likely to administer tPA.
Results
Among
Conclusions
Further efforts to improve appropriate administration of tPA should be encouraged, particularly as the acceptable time-window for using tPA widens.
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John Wiley & Sons, Inc. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Despite guidelines and regulatory agencies promoting the use of thrombolysis for ischemic stroke, previous studies have shown disappointingly low rates of use [9] [10] [11] [12] . The goals of this study were to assess whether national trends in the use of thrombolysis for acute ischemic stroke have increased in light of increased regulatory activity as well as to identify patient characteristics associated with thrombolytic administration. were identified by searching for specific ICD-9-CM codes, including for heart failure, coronary artery disease, hypertension, diabetes mellitus, and atrial fibrillation. To provide a general assessment of the severity of illness of the patients, we calculated an adapted Charlson comorbidity score for each patient using available secondary discharge diagnosis codes 14 . We also searched for codes corresponding to intracranial hemorrhage, a complication associated with tPA administration.
Journal of Hospital Medicine
Materials and Methods
Data
Statistical Analysis
We defined thrombolytic utilization rates as the number of patients hospitalized with a primary diagnosis of ischemic stroke who had a procedure code for thrombolysis divided by the total number of patients hospitalized with ischemic stroke. To calculate nationally representative prevalence rates, we used the sample weights provided by the NHDS to account for the complex sampling design of the survey. Differences in thrombolytic administration rates by patient and Figure 1 ).
On bivariate analysis, a lower proportion of African-American patients received tPA compared to white patients (0.8% vs. 1.5%, p=0.003), while a higher proportion of patients with atrial fibrillation received tPA (2.3% vs. 1.2%, p<0.001). Older patients were less likely than younger patients to receive tPA ( Table 1 ). The rate of intracranial hemorrhage was significantly higher in patients who received tPA (5.4% vs. 0.6%, p<0.001) and the overall inpatient mortality in patients who received tPA was 9.0%. Mortality in patients receiving tPA continued to be Charlson comorbidity index ( Table 2) . Patients aged 80 years or older, African-American patients, and those with diabetes mellitus were significantly less likely to receive thrombolysis.
Discussion
Despite strong recommendations from guidelines and regulatory agencies, national rates of intravenous thrombolysis for ischemic stroke continue to be quite low overall. However, tPA administration appears to have increased from previous years and particularly increased in years after the Joint Commission began to accredit institutions as "Primary Stroke Centers" 11 . The oldest patients and African-Americans were less likely to receive thrombolytics, while patients with atrial fibrillation were more likely to receive thrombolysis, potentially related to atrial fibrillation causing more severe strokes 15 . Five point four percent of patients who received tPA were diagnosed with intracranial hemorrhage, and the inpatient mortality rate of patients with tPA was 9.0%. The exact optimal rate of thrombolysis administration for the patients in our study is unknown, as the NHDS database lacked detailed information on factors that would preclude tPA administration such as late timing of presentation and mild stroke symptoms 3 . Studies conducted in stroke registries and regional settings have found that only approximately 15%-32% of patients presenting with ischemic stroke arrive within 3 hours of symptom onset, and of these, only about 40%-50% are eligible for tPA clinically 9, 10, [16] [17] [18] [19] . However, even among presumed eligible patients, tPA administration rates only range between 25% and 43% 17, 19, 20 , and the ideal rate is likely to be higher than the very low rates we observed in our study. Newer evidence that extending the time window where tPA may be given safely may increase the number of eligible patients 21 .
Patients who received thrombolysis had higher mortality rates than patients who did not.
Although we were unable to determine a causal association, prior observational studies of tPA administration for acute stroke have found that patients with more severe neurologic deficits were more likely to receive thrombolysis 17, 18 . The 9.0% inpatient case-fatality rate observed in our study compares favorably to the 13.4% mortality rate after tPA reported in a post-approval meta-analysis of safety outcomes 22 and the rate of intracranial hemorrhage in our analysis was similar to those observed in other settings 9, [22] [23] [24] [25] . We were unable to determine whether intracranial hemorrhages in our study were as a result of tPA administration or whether patients who received tPA were more likely to have intracranial hemorrhages detected, such as may be due to increased frequency of head imaging.
Larger hospitals were more likely to administer tPA. This may reflect regionalization of stroke care, particularly in those designated as stroke "centers of excellence". As well, there is some evidence that there is a "learning curve" with thrombolysis administration, where 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There are several limitations to our analysis. The NHDS does not collect detailed data on clinical or presenting features of stroke, and so we lacked information on stroke severity and eligibility for administration of thrombolysis. Our study may have underestimated the overall rates of thrombolysis, as it was dependent on diagnostic codes. A previous study of 34 patients who received tPA found that although the 99.10 code was 100% specific, the code identified only 17 patients who actually received tPA (sensitivity of 50%) 20 . Another study comparing
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Medicare administrative claims data to actual pharmacy billing charges for tPA found that administrative data underestimated the rate of tPA administration by about 25%-30% 12 . If a diagnostic code sensitivity of 50% was assumed, rates of tPA administration in our study may have been as high as 4.8% [95% CI: 4.1%-5.5%] by year 2006.
In conclusion, the use of intravenous thrombolysis in patients admitted with acute ischemic stroke in the United States has risen over time, but overall use remains very low.
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